Data are provided by many contributors through the the WHO Clinical data platform and are not necessarily representative. To become a contributor, please see the terms of use and register here.

Total cases

101

Confirmed cases

60

Total PLWH

16

Women

42.6%

Children below 5

13.9%

Total deaths

1

The map below is just a proof of concept. Can be adjusted once/if we have data at the regional level.

Geospatial distribution
Cases reported
Mirror plots
Chronic conditions
Variable Sample size Prevalence pct Frequency
HIV (Human Immunodeficiency Virus) 101 15.8% 16 / 101
Hypertension 101 4.0% 4 / 101
Current new STI (Sexually Transmitted Infection) diagnosis? 101 4.0% 4 / 101
Syphilis 4 100.0% 4 / 4
Current alcohol use disorder 101 1.0% 1 / 101
Immunosuppressive condition 101 1.0% 1 / 101
Chronic heart disease 101 0.0% 0 / 101
Chronic lung disease 101 0.0% 0 / 101
Chronic kidney disease 101 0.0% 0 / 101
Chronic liver disease 101 0.0% 0 / 101
Chronic neurologic condition 101 0.0% 0 / 101
Previous COVID-19 infection 101 0.0% 0 / 101
Diabetes 101 0.0% 0 / 101
Currently smokes tobacco 101 0.0% 0 / 101
Skin Conditions 101 0.0% 0 / 101
Tuberculosis (previous) 101 0.0% 0 / 101
Tuberculosis (active) 101 0.0% 0 / 101
Asplenia 101 0.0% 0 / 101
Cancer 101 0.0% 0 / 101
N. gonorrhoeae 3 0.0% 0 / 3
HSV 3 0.0% 0 / 3
Chlamydia trachomatis 3 0.0% 0 / 3
HPV 3 0.0% 0 / 3
AIDS - defining illness 15 0.0% 0 / 15

Source: WHO
Complications
Variable Sample size Prevalence pct Frequency
Cellulitis 97 25.8% 25 / 97
Bacteraemia 97 11.3% 11 / 97
Abscess 97 5.2% 5 / 97
Anaemia 97 4.1% 4 / 97
Sepsis 97 3.1% 3 / 97
Viral Pneumonia / Pneumonitis 97 3.1% 3 / 97
Bacterial Pneumonia 97 3.1% 3 / 97
Ocular Complications 97 2.1% 2 / 97
Shock 97 1.0% 1 / 97
Encephalitis / Meningitis 97 1.0% 1 / 97
Bleeding Disorder 97 1.0% 1 / 97
Cardiac Arrest 97 1.0% 1 / 97
Cardiac Arrhythmia 97 1.0% 1 / 97
Cardiomyopathy 97 1.0% 1 / 97
Myocarditis / Pericarditis 97 1.0% 1 / 97
Acute Respiratory Distress Syndrome (Ards) 97 1.0% 1 / 97
Urinary Retention 97 1.0% 1 / 97
Necrotizing Infection 97 1.0% 1 / 97
Seizure 97 0.0% 0 / 97
Stroke / Cerebrovascular Accident 97 0.0% 0 / 97
Guillain-Barré Syndrome 97 0.0% 0 / 97
Acute Renal Injury / Acute Renal Failure 97 0.0% 0 / 97
Pancreatitis 97 0.0% 0 / 97
Liver Dysfunction 97 0.0% 0 / 97
Proctitis 97 0.0% 0 / 97
Rectal Urgency 97 0.0% 0 / 97
Rectal Pain 97 0.0% 0 / 97

Source: WHO
Body map of lesions at admission
Prevalence of lesions at admission
Variable Sample size Prevalence pct Frequency
Upper limb 100 85.0% 85/100
Head and neck 100 81.0% 81/100
Lower limb 100 78.0% 78/100
Chest and abdomen 99 77.8% 77/99
Back 100 75.0% 75/100
Genitals 100 51.0% 51/100
Mouth 99 23.2% 23/99

Source: WHO
Type of lesions
Variable Sample size Prevalence pct Frequency
Papule 101 76.2% 77/101
Macule 101 52.5% 53/101
Crusting of a mature lesion 101 38.6% 39/101
Small pustule 101 37.6% 38/101
Umbilicated pustule 101 32.7% 33/101
Ulcerated lesion 101 31.7% 32/101
Early vesicle 101 30.7% 31/101
Partially removed scab 101 17.8% 18/101

Source: WHO
Reported symptoms
Symptoms at admission
Variable Sample size Prevalence pct Frequency
Fever 100 85.0% 85 / 100
Pruritis/itching 100 69.0% 69 / 100
Headache 101 59.4% 60 / 101
Muscle pain or aching 101 51.5% 52 / 101
Fatigue or malaise 101 50.5% 51 / 101
Sore throat 101 40.6% 41 / 101
Joint pain or aching 101 28.7% 29 / 101
Swallowing problem 101 27.7% 28 / 101
Painful swallow 28 96.4% 27 / 28
Pain in mouth 101 24.8% 25 / 101
Urinary symptoms 101 20.8% 21 / 101
Pain with urination 21 100.0% 21 / 21
Psychologic disturbance 101 13.9% 14 / 101
Dizziness 101 10.9% 11 / 101
Difficult swallow 28 28.6% 8 / 28
Nausea 101 6.9% 7 / 101
Ocular symptoms (pain, redness, visual loss) 101 5.0% 5 / 101
Red eye(s) 5 100.0% 5 / 5
Vomiting 101 4.0% 4 / 101
Chest pain 101 4.0% 4 / 101
Decrease urine output 20 20.0% 4 / 20
Diarrhoea 101 3.0% 3 / 101
Eye pain 5 60.0% 3 / 5
Any rectal symptom 101 2.0% 2 / 101
Urethral discharge 21 9.5% 2 / 21
Rectal pain 2 100.0% 2 / 2
Other 5 20.0% 1 / 5
Proctitis 101 0.0% 0 / 101
Rectal discharge 2 0.0% 0 / 2
Rectal urgency/tenesmus 2 0.0% 0 / 2
Visual disturbance 5 0.0% 0 / 5
...with blood 4 0.0% 0 / 4

Source: WHO
Symptoms at discharge
Variable Sample size Prevalence pct Frequency
Pruritis/itching 96 3.1% 3 / 96
Sore throat 97 1.0% 1 / 97
Fever 97 0.0% 0 / 97
Muscle pain or aching 97 0.0% 0 / 97
Headache 97 0.0% 0 / 97
Ocular symptoms (pain, redness, visual loss) 97 0.0% 0 / 97
Fatigue or malaise 97 0.0% 0 / 97
Pain in mouth 97 0.0% 0 / 97
Nausea 97 0.0% 0 / 97
Vomiting 97 0.0% 0 / 97
Diarrhoea 97 0.0% 0 / 97
Any rectal symptom 97 0.0% 0 / 97
Swallowing problem 97 0.0% 0 / 97
Chest pain 97 0.0% 0 / 97
Joint pain or aching 97 0.0% 0 / 97
Proctitis 97 0.0% 0 / 97
Dizziness 97 0.0% 0 / 97
Psychologic disturbance 97 0.0% 0 / 97
Urinary symptoms 97 0.0% 0 / 97

Source: WHO
Variable

Person with HIV
N = 16

Person without HIV
N = 74

Unknown
N = 11

 p-value 1
Age group, n (%)



    28-364 days 0 (0%) 2 (2.7%) 0 (0%)
    1-4 years 0 (0%) 11 (15%) 1 (9.1%)
    5-9 years 0 (0%) 8 (11%) 0 (0%)
    10-14 years 1 (6.3%) 6 (8.1%) 1 (9.1%)
    15-19 years 0 (0%) 5 (6.8%) 0 (0%)
    20-24 years 4 (25%) 18 (24%) 2 (18%)
    25-29 years 2 (13%) 8 (11%) 2 (18%)
    30-34 years 1 (6.3%) 5 (6.8%) 2 (18%)
    35-39 years 3 (19%) 5 (6.8%) 2 (18%)
    40-44 years 2 (13%) 4 (5.4%) 0 (0%)
    45-49 years 0 (0%) 1 (1.4%) 1 (9.1%)
    50-54 years 1 (6.3%) 1 (1.4%) 0 (0%)
    65-69 years 1 (6.3%) 0 (0%) 0 (0%)
    Unknown 1 (6.3%) 0 (0%) 0 (0%)
Sex at birth, n (%)


0.013
    Male 5 (31%) 48 (65%) 4 (36%)
    Female 10 (63%) 26 (35%) 7 (64%)
    Intersex 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (6.3%) 0 (0%) 0 (0%)
Race, n (%)


>0.9
    African/Black 15 (94%) 69 (93%) 11 (100%)
    Arab 0 (0%) 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (6.3%) 5 (6.8%) 0 (0%)
    Other 0 (0%) 0 (0%) 0 (0%)
health care worker, n (%)


0.5
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 15 (94%) 73 (99%) 11 (100%)
    Unknown 1 (6.3%) 1 (1.4%) 0 (0%)
Laboratory worker, n (%)


0.7
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 15 (94%) 71 (96%) 11 (100%)
    Unknown 1 (6.3%) 3 (4.1%) 0 (0%)
Sex worker, n (%)


<0.001
    Yes 7 (44%) 2 (2.7%) 1 (9.1%)
    No 8 (50%) 67 (91%) 10 (91%)
    Unknown 1 (6.3%) 5 (6.8%) 0 (0%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)


>0.9
    Yes 0 (0%) 1 (3.8%) 0 (0%)
    No 10 (100%) 25 (96%) 7 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 6 48 4
Breastfeeding, n (%)



    Yes 0 (NA%) 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%) 0 (NA%)
    Missing/Unknown 16 74 11
1

Fisher’s exact test
Variable

Person with HIV
N = 16

Person without HIV
N = 74

Unknown
N = 11

 p-value 1
ever hospitalized, n (%)


0.4
    Yes 11 (79%) 61 (84%) 10 (100%)
    No 3 (21%) 12 (16%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
Length of hospitalization, Median (Q1, Q3) 12 (5, 15) 7 (5, 12) 7 (4, 11) 0.2
    Missing/Unknown 5 13 1
Escalation of care, n (%)


0.063
    Yes 1 (9.1%) 0 (0%) 1 (10%)
    No 10 (91%) 61 (100%) 9 (90%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 5 13 1
supplemental oxygen, n (%)


0.063
    Yes 1 (9.1%) 0 (0%) 0 (0%)
    No 10 (91%) 61 (100%) 9 (90%)
    Unknown 0 (0%) 0 (0%) 1 (10%)
    Missing/Unknown 5 13 1
receive nasogastric fluids, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 14 (100%) 73 (100%) 10 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
receive IV fluids during course monkeypox infection, n (%)


0.039
    Yes 2 (14%) 2 (2.7%) 2 (20%)
    No 12 (86%) 71 (97%) 8 (80%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
receive analgesia for pain management, n (%)


0.004
    Yes 10 (71%) 24 (33%) 7 (70%)
    No 4 (29%) 49 (67%) 3 (30%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
receive antibiotics during course monkeypox infection, n (%)


0.8
    Yes 13 (93%) 66 (90%) 10 (100%)
    No 1 (7.1%) 7 (9.6%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
receive antifungals during course monkeypox infection, n (%)


0.2
    Yes 1 (7.1%) 0 (0%) 0 (0%)
    No 13 (93%) 73 (100%) 10 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
experimental antiviral during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 14 (100%) 73 (100%) 10 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
1

Fisher’s exact test; Kruskal-Wallis rank sum test
Variable

Person with HIV
N = 16

Person without HIV
N = 74

Unknown
N = 11

 p-value 1
History of tetanus vaccination, n (%)


0.5
    Yes 0 (0%) 7 (9.5%) 2 (18%)
    No 5 (31%) 29 (39%) 4 (36%)
    Unknown 11 (69%) 38 (51%) 5 (45%)
History of smallpox vaccination before 1980, n (%)


0.7
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 13 (81%) 63 (85%) 9 (82%)
    Unknown 3 (19%) 11 (15%) 2 (18%)
History of smallpox or monkeypox vaccination in past year, n (%)


0.3
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 15 (94%) 69 (93%) 9 (82%)
    Unknown 1 (6.3%) 5 (6.8%) 2 (18%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 16 74 11
1

Fisher’s exact test
Variable

Person with HIV
N = 16

Person without HIV
N = 74

Unknown
N = 11

 p-value 1
New diagnosis of HIV, n (%)


0.13
    Yes 0 (0%) 1 (1.4%) 1 (10%)
    No 13 (100%) 71 (97%) 8 (80%)
    Unknown 0 (0%) 1 (1.4%) 1 (10%)
    Missing/Unknown 3 1 1
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 3 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 13 74 11
Immunosuppressive condition, n (%)


0.003
    Yes 1 (6.3%) 0 (0%) 0 (0%)
    No 15 (94%) 74 (100%) 9 (82%)
    Unknown 0 (0%) 0 (0%) 2 (18%)
Most recent CD4, Median (Q1, Q3) 98 (98, 98) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 1 74 11
Viral load, n (%)



    Detectable 0 (0%) 0 (NA%) 0 (NA%)
    Undetectable 3 (20%) 0 (NA%) 0 (NA%)
    Unknown 12 (80%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 74 11
AIDS - defining illness, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 15 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 74 11
1

Fisher’s exact test
Skin lesions by HIV status
Complications by HIV status
    Variable

    Confirmed case
    N = 60

    Not confirmed
    N = 36

    		 p-value 1
    HIV status, n (%)

    		<0.001
        Person with HIV 13 (22%) 1 (2.8%)
        Person without HIV 37 (62%) 35 (97%)
        Unknown 10 (17%) 0 (0%)
    Age group, n (%)

    		0.2
        28-364 days 1 (1.7%) 1 (2.8%)
        1-4 years 6 (10%) 5 (14%)
        5-9 years 2 (3.3%) 6 (17%)
        10-14 years 4 (6.7%) 4 (11%)
        15-19 years 2 (3.3%) 3 (8.3%)
        20-24 years 16 (27%) 8 (22%)
        25-29 years 6 (10%) 5 (14%)
        30-34 years 6 (10%) 1 (2.8%)
        35-39 years 9 (15%) 1 (2.8%)
        40-44 years 4 (6.7%) 1 (2.8%)
        45-49 years 2 (3.3%) 0 (0%)
        50-54 years 1 (1.7%) 1 (2.8%)
        65-69 years 1 (1.7%) 0 (0%)
        Unknown 0 (0%) 0 (0%)
    Sex at birth, n (%)

    		0.2
        Male 31 (52%) 24 (67%)
        Female 29 (48%) 12 (33%)
        Intersex 0 (0%) 0 (0%)
        Unknown 0 (0%) 0 (0%)
    Race, n (%)

    		>0.9
        African/Black 57 (95%) 34 (94%)
        Arab 0 (0%) 0 (0%)
        Asian 0 (0%) 0 (0%)
        Hispanic/Latino 0 (0%) 0 (0%)
        Mixed Race 0 (0%) 0 (0%)
        White 0 (0%) 0 (0%)
        Unknown 3 (5.0%) 2 (5.6%)
        Other 0 (0%) 0 (0%)
    health care worker, n (%)

    		>0.9
        Yes 0 (0%) 0 (0%)
        No 59 (98%) 36 (100%)
        Unknown 1 (1.7%) 0 (0%)
    Laboratory worker, n (%)

    		0.6
        Yes 0 (0%) 0 (0%)
        No 59 (98%) 34 (94%)
        Unknown 1 (1.7%) 2 (5.6%)
    Sex worker, n (%)

    		0.032
        Yes 9 (15%) 0 (0%)
        No 48 (80%) 34 (94%)
        Unknown 3 (5.0%) 2 (5.6%)
    currently pregnant or was pregnant in the last 6 weeks?, n (%)

    		0.3
        Yes 0 (0%) 1 (8.3%)
        No 29 (100%) 11 (92%)
        Unknown 0 (0%) 0 (0%)
        Missing/Unknown 31 24
    Breastfeeding, n (%)


        Yes 0 (NA%) 0 (NA%)
        No 0 (NA%) 0 (NA%)
        Unknown 0 (NA%) 0 (NA%)
        Missing/Unknown 60 36
    1

    Fisher’s exact test
    Variable

    Confirmed case
    N = 60

    Not confirmed
    N = 36

    		 p-value 1
    HIV status, n (%)

    		<0.001
        Person with HIV 13 (22%) 1 (2.8%)
        Person without HIV 37 (62%) 35 (97%)
        Unknown 10 (17%) 0 (0%)
    ever hospitalized, n (%)

    		0.2
        Yes 53 (88%) 28 (78%)
        No 7 (12%) 8 (22%)
        Unknown 0 (0%) 0 (0%)
    Length of hospitalization, Median (Q1, Q3) 9 (6, 13) 5 (4, 10) 0.015
        Missing/Unknown 7 8
    Escalation of care, n (%)

    		>0.9
        Yes 1 (1.9%) 1 (3.6%)
        No 52 (98%) 27 (96%)
        Unknown 0 (0%) 0 (0%)
        Missing/Unknown 7 8
    supplemental oxygen, n (%)

    		0.6
        Yes 0 (0%) 1 (3.6%)
        No 52 (98%) 27 (96%)
        Unknown 1 (1.9%) 0 (0%)
        Missing/Unknown 7 8
    receive nasogastric fluids, n (%)

    		>0.9
        Yes 0 (0%) 0 (0%)
        No 60 (100%) 36 (100%)
        Unknown 0 (0%) 0 (0%)
    receive IV fluids during course monkeypox infection, n (%)

    		0.4
        Yes 5 (8.3%) 1 (2.8%)
        No 55 (92%) 35 (97%)
        Unknown 0 (0%) 0 (0%)
    receive analgesia for pain management, n (%)

    		0.003
        Yes 33 (55%) 8 (22%)
        No 27 (45%) 28 (78%)
        Unknown 0 (0%) 0 (0%)
    receive antibiotics during course monkeypox infection, n (%)

    		>0.9
        Yes 56 (93%) 33 (92%)
        No 4 (6.7%) 3 (8.3%)
        Unknown 0 (0%) 0 (0%)
    receive antifungals during course monkeypox infection, n (%)

    		>0.9
        Yes 1 (1.7%) 0 (0%)
        No 59 (98%) 36 (100%)
        Unknown 0 (0%) 0 (0%)
    experimental antiviral during course monkeypox infection, n (%)

    		>0.9
        Yes 0 (0%) 0 (0%)
        No 60 (100%) 36 (100%)
        Unknown 0 (0%) 0 (0%)
    1

    Fisher’s exact test; Wilcoxon rank sum test
    Variable

    Confirmed case
    N = 60

    Not confirmed
    N = 36

    		 p-value 1
    HIV status, n (%)

    		<0.001
        Person with HIV 13 (22%) 1 (2.8%)
        Person without HIV 37 (62%) 35 (97%)
        Unknown 10 (17%) 0 (0%)
    History of tetanus vaccination, n (%)

    		0.4
        Yes 4 (6.7%) 5 (14%)
        No 25 (42%) 12 (33%)
        Unknown 31 (52%) 19 (53%)
    History of smallpox vaccination before 1980, n (%)

    		>0.9
        Yes 0 (0%) 0 (0%)
        No 51 (85%) 31 (86%)
        Unknown 9 (15%) 5 (14%)
    History of smallpox or monkeypox vaccination in past year, n (%)

    		0.7
        Yes 0 (0%) 0 (0%)
        No 55 (92%) 34 (94%)
        Unknown 5 (8.3%) 2 (5.6%)
    Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
        Missing/Unknown 60 36
    1

    Fisher’s exact test
    Variable

    Confirmed case
    N = 60

    Not confirmed
    N = 36

    		 p-value 1
    HIV status, n (%)

    		<0.001
        Person with HIV 13 (22%) 1 (2.8%)
        Person without HIV 37 (62%) 35 (97%)
        Unknown 10 (17%) 0 (0%)
    New diagnosis of HIV, n (%)

    		0.8
        Yes 2 (3.4%) 0 (0%)
        No 56 (95%) 35 (97%)
        Unknown 1 (1.7%) 1 (2.8%)
        Missing/Unknown 1 0
    Current new STI (Sexually Transmitted Infection) diagnosis, n (%)


        Yes 0 (0%) 0 (NA%)
        No 3 (100%) 0 (NA%)
        Unknown 0 (0%) 0 (NA%)
        Missing/Unknown 57 36
    Immunosuppressive condition, n (%)

    		0.5
        Yes 0 (0%) 0 (0%)
        No 58 (97%) 36 (100%)
        Unknown 2 (3.3%) 0 (0%)
    Most recent CD4, Median (Q1, Q3) 98 (98, 98) 98 (98, 98) 0.8
        Missing/Unknown 47 35
    Viral load, n (%)

    		>0.9
        Detectable 0 (0%) 0 (0%)
        Undetectable 3 (23%) 0 (0%)
        Unknown 10 (77%) 1 (100%)
        Missing/Unknown 47 35
    AIDS - defining illness, n (%)

    		>0.9
        Yes 0 (0%) 0 (0%)
        No 13 (100%) 1 (100%)
        Unknown 0 (0%) 0 (0%)
        Missing/Unknown 47 35
    1

    Fisher’s exact test; Wilcoxon rank sum test
    Skin lesions by mpox status
    Complications
    Exposure distribution
    Variable Sample size Prevalence pct Frequency
    Sexually active within ≤ 21 days prior to symptom onset? 101 45.5% 46/101
    Number of heterosexual partners in the last three months 44 75.0% 33/44
    Any known link to probable or confirmed case of monkeypox within ≤ 21 days prior to symptom onset? 101 11.9% 12/101
    International travel within ≤ 21 days prior to symptom onset? 101 4.0% 4/101
    Contact with possible animal source within ≤ 21 days prior to symptom onset? 101 0.0% 0/101
    Did the patient receive experimental antiviral during course monkeypox infection? 97 0.0% 0/97

    Source: WHO
    Variable N = 101
    Mpox clade known:, n (%)
        Yes 0 (0%)
        No 97 (100%)
        Unknown 0 (0%)
        Missing/Unknown 4
    Mpox clade, n (%)
        Ia 0 (NA%)
        Ib 0 (NA%)
        IIa 0 (NA%)
        IIb 0 (NA%)
        Missing/Unknown 101
    Monkeypox PCR, n (%)
        Yes 96 (99%)
        No 1 (1.0%)
        Unknown 0 (0%)
        Missing/Unknown 4
    Monkeypox Result, n (%)
        Positive 60 (63%)
        Negative 34 (35%)
        Indeterminate 0 (0%)
        Unknown 2 (2.1%)
        Missing/Unknown 5
    Monkeypox viral culture, n (%)
        Yes 0 (0%)
        No 97 (100%)
        Unknown 0 (0%)
        Missing/Unknown 4
    Monkeypox viral culture Result, n (%)
        Positive 0 (NA%)
        Negative 0 (NA%)
        Indeterminate 0 (NA%)
        Unknown 0 (NA%)
        Missing/Unknown 101
    Variable N = 101
    Orthopoxvirus PCR, n (%)
        Yes 0 (0%)
        No 97 (100%)
        Unknown 0 (0%)
        Missing/Unknown 4
    Orthopoxvirus Result, n (%)
        Positive 0 (NA%)
        Negative 0 (NA%)
        Indeterminate 0 (NA%)
        Unknown 0 (NA%)
        Missing/Unknown 101
    Variable N = 101
    Malaria result, n (%)
        Positive 0 (0%)
        Negative 5 (100%)
        Indeterminate 0 (0%)
        Unknown 0 (0%)
        Missing/Unknown 96
    Syphilis result, n (%)
        Positive 2 (67%)
        Negative 1 (33%)
        Indeterminate 0 (0%)
        Unknown 0 (0%)
        Missing/Unknown 98
    Variable

    Baseline visit
    N = 101
    Hemoglobin, Median (Q1, Q3) 14.30 (11.30, 15.90)
    WCC total, Median (Q1, Q3) 7.70 (6.70, 10.40)
    Platelets, Median (Q1, Q3) 256 (159, 352)
    PT, Median (Q1, Q3) NA (NA, NA)
    APTT, Median (Q1, Q3) NA (NA, NA)
    Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
    ALT, Median (Q1, Q3) NA (NA, NA)
    AST, Median (Q1, Q3) NA (NA, NA)
    Na+, Median (Q1, Q3) NA (NA, NA)
    K+, Median (Q1, Q3) NA (NA, NA)
    Urea/BUN, Median (Q1, Q3) NA (NA, NA)
    Creatinine, Median (Q1, Q3) NA (NA, NA)
    Glucose, Median (Q1, Q3) NA (NA, NA)
    Lactate, Median (Q1, Q3) NA (NA, NA)
    CRP, Median (Q1, Q3) NA (NA, NA)
    Creatine kinase, Median (Q1, Q3) NA (NA, NA)
    Variable

    During infection management
    N = 212
    Hemoglobin, Median (Q1, Q3) 13.20 (11.40, 15.60)
    WCC total, Median (Q1, Q3) 7.60 (6.40, 9.50)
    Platelets, Median (Q1, Q3) 274 (190, 369)
    PT, Median (Q1, Q3) NA (NA, NA)
    APTT, Median (Q1, Q3) NA (NA, NA)
    Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
    ALT, Median (Q1, Q3) 22 (22, 22)
    AST, Median (Q1, Q3) 34 (34, 34)
    Na+, Median (Q1, Q3) 134 (134, 134)
    K+, Median (Q1, Q3) 4.1600 (4.1600, 4.1600)
    Urea/BUN, Median (Q1, Q3) 6.3564 (6.3564, 6.3564)
    Creatinine, Median (Q1, Q3) 32.7154 (32.7154, 32.7154)
    Glucose, Median (Q1, Q3) NA (NA, NA)
    Lactate, Median (Q1, Q3) NA (NA, NA)
    CRP, Median (Q1, Q3) NA (NA, NA)
    Creatine kinase, Median (Q1, Q3) NA (NA, NA)
    Variables Lab measures distribution
    N Mean Median Min Max Distribution
    Baseline visit
    Hemoglobin 23.00 13.71 14.30 6.30 18.60
    Platelets 23.00 281.39 256.00 71.00 731.00
    WCC total 22.00 8.78 7.70 3.00 29.00
    Outcomes